Alzamend Neuro Inc. Stock
€0.13
Your prediction
Financial data and news for Alzamend Neuro Inc.
sharewise wants to provide you with the best news and tools for Alzamend Neuro Inc., so we directly link to the best financial data sources.
Financials
News
![Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel: https://mms.businesswire.com/media/20210804005491/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKy92Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cef2f54932d3c409039cc4fa6fab82e7f5480941/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg?locale=us)
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar
![Alzamend Neuro Announces Initial Closing of Private Placement : https://mms.businesswire.com/media/20210804005491/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKy92Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cef2f54932d3c409039cc4fa6fab82e7f5480941/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg?locale=us)
Alzamend Neuro Announces Initial Closing of Private Placement
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar
![Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million: https://mms.businesswire.com/media/20210804005491/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKy92Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cef2f54932d3c409039cc4fa6fab82e7f5480941/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg?locale=us)
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar
![Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program: https://mms.businesswire.com/media/20210804005491/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKy92Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cef2f54932d3c409039cc4fa6fab82e7f5480941/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg?locale=us)
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar